Editing Abbott Laboratories (section)

=== International expansion ===
Abbott's first international affiliate was in London in 1907; the company later added an affiliate in Montreal, Canada.{{citation needed|date=June 2020}} Abbott India Ltd was originally incorporated on August 22, 1944, as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1, 1971, and to Boots Pharmaceuticals Ltd on January 1, 1991. On October 31, 1995, the name was changed to Knoll Pharmaceuticals Ltd and on July 1, 2002, to their present name Abbott India Ltd. Abbott started operations in Pakistan as a marketing affiliate in 1948; the company has steadily expanded to comprise a work force of over 1500 employees. Currently, two manufacturing facilities located at Landhi and Korangi in [[Karachi]] continue to produce pharmaceutical products.<ref>{{Cite web|url=https://www.pk.abbott/homepage.html|title=Abbott in Pakistan &#124; Abbott|website=www.pk.abbott|access-date=5 July 2023|archive-date=18 June 2021|archive-url=https://web.archive.org/web/20210618065938/https://www.pk.abbott/homepage.html|url-status=live}}</ref> In 1962  Abbott entered into a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radio-pharmaceuticals.{{citation needed|date=June 2020}} In 1964, it merged with Ross Laboratories, making Ross a wholly owned subsidiary of Abbott, and Richard Ross gained a seat on Abbott's board of directors until his retirement in 1983.<ref>{{cite web|url=https://www.chicagotribune.com/news/ct-xpm-1993-12-11-9312110107-story.html|title=RICHARD MOORE ROSS, 77, ABBOTT LABS EXECUTIVE|first=Chicago|last=Tribune|website=Chicago Tribune|date=11 December 1993|access-date=2 June 2019|archive-date=30 September 2022|archive-url=https://web.archive.org/web/20220930075607/https://www.chicagotribune.com/news/ct-xpm-1993-12-11-9312110107-story.html|url-status=live}}</ref> The acquisition of Ross brought Similac under the Abbott umbrella. In the years following the acquisition, Pedialyte and Ensure were introduced as nutritional products by Ross Laboratories while under Abbott's leadership.<ref>{{Cite web |url=https://ohiohistorycentral.org/w/Ross_Laboratories |title=Ross Laboratories - Ohio History Central |website=ohiohistorycentral.org |access-date=2020-04-02 |archive-date=30 September 2022 |archive-url=https://web.archive.org/web/20220930000742/https://ohiohistorycentral.org/w/Ross_Laboratories |url-status=live }}</ref><ref>{{Cite web |url=https://www.dispatch.com/business/20190222/abbott-labs-plans-62-million-investment-in-columbus |title=Abbott Labs plans $62 million investment in Columbus |last=Rose |first=Marla Matzer |website=The Columbus Dispatch |language=en |access-date=2020-04-02 |archive-date=20 August 2020 |archive-url=https://web.archive.org/web/20200820173356/https://www.dispatch.com/business/20190222/abbott-labs-plans-62-million-investment-in-columbus |url-status=dead }}</ref><ref>{{Cite web |url=https://oilcity.news/general/2020/01/10/welcome-sherri-blanchard-m-d-to-douglas-primary-care/ |title=Welcome Sherri Blanchard, M.D., to Douglas Primary Care – Casper, WY Oil City News |date=2020-01-10 |website=Oil City News |language=en-US |access-date=2020-04-02 |archive-date=29 November 2022 |archive-url=https://web.archive.org/web/20221129201413/https://oilcity.news/general/2020/01/10/welcome-sherri-blanchard-m-d-to-douglas-primary-care/ |url-status=live }}</ref>

In 1965, Abbott's expansion in Europe continued with offices in Italy and France.{{citation needed|date=December 2022}}

According to Harvard professor [[Lester Grinspoon]] and Peter Hedblom, "In 1966 Abbott Laboratories sold the equivalent of two million doses of [[methamphetamine]] in powder form to a Long Island criminal dealer".<ref name="grinspoon23">{{cite book|last1=Grinspoon|first1=Lester|last2=Hedblom|first2=Peter|title=The Speed Culture: Amphetamine Use and Abuse in America|date=1975|publisher=Harvard University Press|location=Cambridge, Massachusetts|isbn=9780674831926|oclc=1362148|page=[https://archive.org/details/speedcultureamph0000grin_n3i0/page/23 23]|url=https://archive.org/details/speedcultureamph0000grin_n3i0|url-access=registration|quote=strasenburgh prescription.}}</ref>

In 1985, Abbott partnered with the Japanese company [[Taisho Pharmaceutical]] for the international rights to [[clarithromycin]], a second-generation [[macrolide]] [[antibiotic]], and gained FDA approval for the drug under the brand name Biaxin in October 1991. The drug went [[Generic drug|generic]] in Europe in 2004 and in the US in mid-2005,<ref name="pmid25165548">{{cite journal | vauthors = Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk A | title = Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports | journal = Therapeutic Advances in Infectious Disease | volume = 1 | issue = 4 | pages = 121–138 | date = August 2013 | pmid = 25165548 | pmc = 4040724 | doi = 10.1177/2049936113497203 }}</ref> and has been added to the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO-2019">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 21st list 2019 | year = 2019 | hdl = 10665/325771 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref>